Staar Surgical Price Target Cut to $44.00/Share From $50.00 by Stifel
Staar Surgical Analyst Ratings
Stifel Maintains Staar Surgical(STAA.US) With Buy Rating, Cuts Target Price to $44
CCORF Maintains Staar Surgical(STAA.US) With Hold Rating, Maintains Target Price $41
Analysts Conflicted on These Healthcare Names: Merus (MRUS), Staar Surgical (STAA) and Rani Therapeutics Holdings (RANI)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Staar Surgical (STAA) and Organon (OGN)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Cadrenal Therapeutics, Inc. (CVKD) and Allogene Therapeutics (ALLO)
Staar Surgical Hold Rating: Solid Performance Amid Global Economic Uncertainty and China Market Concerns
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Staar Surgical (STAA) and Pliant Therapeutics (PLRX)
Staar Surgical Analyst Ratings
Staar Surgical (STAA) Gets a Hold From Needham
Stifel Maintains Staar Surgical(STAA.US) With Buy Rating, Maintains Target Price $50
Stifel Nicolaus Sticks to Their Buy Rating for Staar Surgical (STAA)
Morgan Stanley Cuts STAAR to Underweight, Cites Growth Expectations
Morgan Stanley Downgrades Staar Surgical to Underweight, Lowers Price Target to $37
Staar Surgical Analyst Ratings
Staar Surgical Analyst Ratings
BTIG Upgrades Staar Surgical to Buy, Announces $46 Price Target
Staar Surgical: A Hold Rating Amidst Conservative Guidance and Modest Growth Prospects
Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $43